@ARTICLE{
author={Dimopoulos Meletios Athanasios|,Terpos Evangelos|,Boccadoro Mario|,Delimpasi Sosana|,Beksac Meral|,Katodritou Eirini|,Moreau Philippe|,Baldini Luca|,Symeonidis Argiris|,Bila Jelena S|0000-0003-2025-9653,Oriol Albert|,Mateos Maria-Victoria|,Einsele Hermann|,Orfanidis Ioannis|,Kampfenkel Tobias|,Liu Weiping|,Kosh Michele|,NamPhuong Tran|,Carson Robin|,Sonneveld Pieter|},
year={2022},
title={Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study},
journal={BLOOD},
volume={140},
number={},
pages={7272-7274},
document_type={Meeting Abstract},
}